Inhibitors of nitric oxide synthase to treat type 1 diabetes
AssigneeMUSC Foundation for Research Development
InventorInderjit Singh
Life of this patent
Estimating the term…
Abstract
A method for treating type 1 diabetes in a human in need of such treatment, comprising administering to the human a biologically effective amount of at least one inhibitor of inducible nitric oxide synthase or a pro-inflammatory cytokine, wherein the inhibitor is an inhibitor of HMG-CoA reductase or a pharmaceutically acceptable salt thereof, and the inhibitor specifically inhibits the activity of HMG-CoA reductase.
Claims36
A method for treating type 1 diabetes in a human in need of such treatment, comprising administering to the human a biologically effective amount of at least one inhibitor of inducible nitric oxide synthase, wherein the inhibitor is an inhibitor of HMG-CoA reductase or a pharmaceutically acceptable salt thereof, and the inhibitor specifically inhibits the activity of HMG-CoA reductase.
A method for treating type 1 diabetes in a human in need of such treatment, comprising administering to the human a unit dosage form comprising a biologically effective amount of an inhibitor of HMG-CoA reductase or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein the inhibitor specifically inhibits the activity of HMG-CoA reductase.
A method for treating type 1 diabetes in a human in need of such treatment, comprising administering to the human a biologically effective amount of an inhibitor of HMG-CoA reductase or a pharmaceutically acceptable salt thereof, wherein the inhibitor specifically inhibits the activity of HMG-CoA reductase.
Dependencies are inferred from the claim text.